A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Objectives: Intravaginal testosterone has emerged as a potential treatment for vulvovaginal atrophy (VVA) in women, in general, and women taking an aromatase inhibitor (AI). A systematic review of the literature was undertaken to determine whether available clinical trial data support efficacy and safety of intravaginal testosterone for the treatment of VVA. Methods: Scopus, MEDLINE, EMBASE, and the Cochrane Library databases were systematically searched on July 26, 2017, for human studies published in English of clinical trials of intravaginal testosterone. Results: Six separate clinical trials were identified that ranged in size from 10 to 80 participants, with either single dose, or durations of 4 to 12 weeks. Only one study incorporated a double-blind design. Three studies were of women taking an AI. Taken together, the studies suggest that intravaginal testosterone may lower vaginal pH, increase the proportion of vaginal lactobacilli, and possibly improve the vaginal maturation index. The lack of a placebo treatment in four studies, and failure to adjust for baseline differences, resulted in uncertainty of the effect on sexual function. Safety remains uncertain because of the small number of women exposed, short study durations, and inconsistent and incomplete outcome reporting for sex steroid levels. Conclusion: Adequately powered double-blind, placebo-controlled clinical trials of intravaginal testosterone therapy are needed to establish both efficacy and safety.

Original languageEnglish
Pages (from-to)704-709
Number of pages6
JournalMenopause
Volume25
Issue number6
DOIs
Publication statusPublished - 1 Jun 2018

Keywords

  • Intravaginal
  • Testosterone
  • Vulvovaginal atrophy

Cite this

@article{f6d2434c98c1407d9e9f766abd9b295e,
title = "A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy",
abstract = "Objectives: Intravaginal testosterone has emerged as a potential treatment for vulvovaginal atrophy (VVA) in women, in general, and women taking an aromatase inhibitor (AI). A systematic review of the literature was undertaken to determine whether available clinical trial data support efficacy and safety of intravaginal testosterone for the treatment of VVA. Methods: Scopus, MEDLINE, EMBASE, and the Cochrane Library databases were systematically searched on July 26, 2017, for human studies published in English of clinical trials of intravaginal testosterone. Results: Six separate clinical trials were identified that ranged in size from 10 to 80 participants, with either single dose, or durations of 4 to 12 weeks. Only one study incorporated a double-blind design. Three studies were of women taking an AI. Taken together, the studies suggest that intravaginal testosterone may lower vaginal pH, increase the proportion of vaginal lactobacilli, and possibly improve the vaginal maturation index. The lack of a placebo treatment in four studies, and failure to adjust for baseline differences, resulted in uncertainty of the effect on sexual function. Safety remains uncertain because of the small number of women exposed, short study durations, and inconsistent and incomplete outcome reporting for sex steroid levels. Conclusion: Adequately powered double-blind, placebo-controlled clinical trials of intravaginal testosterone therapy are needed to establish both efficacy and safety.",
keywords = "Intravaginal, Testosterone, Vulvovaginal atrophy",
author = "Bell, {Robin J.} and Farwa Rizvi and Islam, {Rakabul M.} and Davis, {Susan R.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1097/GME.0000000000001052",
language = "English",
volume = "25",
pages = "704--709",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams & Wilkins",
number = "6",

}

A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy. / Bell, Robin J.; Rizvi, Farwa; Islam, Rakabul M.; Davis, Susan R.

In: Menopause, Vol. 25, No. 6, 01.06.2018, p. 704-709.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy

AU - Bell, Robin J.

AU - Rizvi, Farwa

AU - Islam, Rakabul M.

AU - Davis, Susan R.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Objectives: Intravaginal testosterone has emerged as a potential treatment for vulvovaginal atrophy (VVA) in women, in general, and women taking an aromatase inhibitor (AI). A systematic review of the literature was undertaken to determine whether available clinical trial data support efficacy and safety of intravaginal testosterone for the treatment of VVA. Methods: Scopus, MEDLINE, EMBASE, and the Cochrane Library databases were systematically searched on July 26, 2017, for human studies published in English of clinical trials of intravaginal testosterone. Results: Six separate clinical trials were identified that ranged in size from 10 to 80 participants, with either single dose, or durations of 4 to 12 weeks. Only one study incorporated a double-blind design. Three studies were of women taking an AI. Taken together, the studies suggest that intravaginal testosterone may lower vaginal pH, increase the proportion of vaginal lactobacilli, and possibly improve the vaginal maturation index. The lack of a placebo treatment in four studies, and failure to adjust for baseline differences, resulted in uncertainty of the effect on sexual function. Safety remains uncertain because of the small number of women exposed, short study durations, and inconsistent and incomplete outcome reporting for sex steroid levels. Conclusion: Adequately powered double-blind, placebo-controlled clinical trials of intravaginal testosterone therapy are needed to establish both efficacy and safety.

AB - Objectives: Intravaginal testosterone has emerged as a potential treatment for vulvovaginal atrophy (VVA) in women, in general, and women taking an aromatase inhibitor (AI). A systematic review of the literature was undertaken to determine whether available clinical trial data support efficacy and safety of intravaginal testosterone for the treatment of VVA. Methods: Scopus, MEDLINE, EMBASE, and the Cochrane Library databases were systematically searched on July 26, 2017, for human studies published in English of clinical trials of intravaginal testosterone. Results: Six separate clinical trials were identified that ranged in size from 10 to 80 participants, with either single dose, or durations of 4 to 12 weeks. Only one study incorporated a double-blind design. Three studies were of women taking an AI. Taken together, the studies suggest that intravaginal testosterone may lower vaginal pH, increase the proportion of vaginal lactobacilli, and possibly improve the vaginal maturation index. The lack of a placebo treatment in four studies, and failure to adjust for baseline differences, resulted in uncertainty of the effect on sexual function. Safety remains uncertain because of the small number of women exposed, short study durations, and inconsistent and incomplete outcome reporting for sex steroid levels. Conclusion: Adequately powered double-blind, placebo-controlled clinical trials of intravaginal testosterone therapy are needed to establish both efficacy and safety.

KW - Intravaginal

KW - Testosterone

KW - Vulvovaginal atrophy

UR - http://www.scopus.com/inward/record.url?scp=85047150078&partnerID=8YFLogxK

U2 - 10.1097/GME.0000000000001052

DO - 10.1097/GME.0000000000001052

M3 - Review Article

VL - 25

SP - 704

EP - 709

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 6

ER -